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VIRAL INFECTIONS: A SURVEY OF PEDIATRIC BLOOD AND MARROW
TRANSPLANT CONSORTIUM INSTITUTIONS
Olson, E.A.1, Fisher, V.2. 1Children’s Healthcare of Atlanta, Atlanta,
GA; 2Rainbow Babies and Children’s Hospital, Ireland Cancer Center,
Cleveland, OH.
This survey was designed to identify viral management practices
and to develop a standard of care for management of viral infections
within the Pediatric Blood and Marrow Transplant Consortium
(PBMTC).
A survey was distributed to members of the PBMTC nursing dis-
cipline. It was designed to collect information about viral infection
management.
Twenty-five percent of the surveys were returned. Both alloge-
neic and autologous transplant procedures were performed at all in-
stitutions. The majority of institutions performed inpatient BMTs,
22% performed outpatient. Non-myeloablative transplants were
performed by 89% of the institutions.
All institutions used some type of viral prophylaxis during trans-
plant, 56% used prophylaxis for all patients. The remaining re-
ported using prophylaxis for herpes simplex positive recipient or
donor, 25% reported using prophylaxis for varicella zoster positive
patients, and 50% used prophylaxis for cytomegalovirus (CMV)
positive donor or recipient. 44% used Acyclovir for prophylaxis
and the others (56%) reported using Acyclovir, Gancyclovir,
IVIG, Valacyclovir or Valgancyclovir. Prophylaxis was started
pre-transplant at 55% of the institutions. The others reported start-
ing prophylaxis day 11 (50%), and 50% started at engraftment for
CMV positive patients. Prophylaxis was stopped when the patient
was off immunosuppressants by 33%, at day121 (11%), six months
(11%), engraftment (11%) the other 34% did not specify. 66% con-
tinued prophylaxis for cGVHD, a third continued until 3 months
off treatment and 16% continued until 6 months off treatment.
Forty-four percent routinely screen for viral infections in both
autologous and allogeneic transplants, 11% reported not routinely
screening. The majority (88%) screened for CMV by PCR in allo-
geneic patients and 12% reported screening for CMV and adenovi-
rus.
There were age specific visitor restrictions at 55% of the institu-
tions. 78% reported no change in isolation practice during high-risk
periods (usually fall-winter) to prevent community viral infections,
22% reported changes if it was prevalent in the community.
Based on the submitted surveys the PBMTC institutions employ
various viral management practices. These findings suggest a need
to develop a viral management standard of care for the pediatric
BMT patient. Further exploration of practices and outcomes is
needed to expand evidence based viral management practices in
the pediatric BMT patient.231
INTENSIVE CARE UNIT ADMISSION OF PEDIATRIC HSCT PATIENTS FOL-
LOWING INITIAL TRANSPLANT DISCHARGE
Duncan, C., Buonanno, M., Clark, J., Lehmann, L. Dana-Farber Can-
cer Institute, Boston, MA.
Intensive care unit (ICU) admission during the primary hemato-
poietic stem cell transplant (HSCT) admission is associated with
a poor, but recently improving, prognosis. The outcome following
intensive care during subsequent admissions is less well studied.We
performed a retrospective review of all patients transplanted be-
tween January 1, 2002 and December 31, 2006 at our institution
and identified ICU admissions subsequent to initial HSCT dis-
charge. Patients admitted to the ICU following disease relapse
were not included in this study. 292 patients underwent 341 trans-
plants during the study period. The mean age of transplanted pa-
tients was 8.9 years (median 7.83 years). Twenty patients had
a total of 24 ICU admissions. Two patients had multiple ICU ad-
missions during a single hospital stay. One patient had 2 ICU stays
during 2 separate admissions. The mean age of these patients was
12.3 years at time of HSCT (median 12.2 years). The average
time from HSCT to readmission was 347.4 days (range 9–881
days). The reasons for admission included respiratory failure (12),sepsis (6), cardiac failure (3), seizure (1), gastrointestinal bleeding
(1), and hepatic failure (1). Twelve patients were intubated for an av-
erage duration of 9 days (range 1–29 days). Three patients were in-
tubated more than once during separate ICU admissions. The
average length of ICU stay was 9.8 days. Eleven (55%) patients
died during the admission in which they received intensive care.
The mean age of the patients that died was 14 years. Eight patients
died following parental decision to withdraw support while the re-
maining 3 patients died receiving maximum support. Only 2 of the
12 intubated patients survived to hospital discharge. Causes of death
included respiratory failure (5), multi-system organ failure (3), car-
diac arrest (2), and a neurologic event (1). Five patients died later; 2
due to relapse and 3 from pulmonary disease. 6.8% of patients un-
dergoing HSCT at our institution over a 5 year time period were
admitted to the ICU following initial HSCT discharge. Ultimately,
14/20 of these patients died of treatment related causes. While
mortality was high for this group there are 4 long-term survivors:
2 admitted with sepsis, 1 for seizure management, and 1 for myosi-
tis-associated respiratory failure. Three of the 4 survivors were
admitted to the ICU for less than 36 hours. Further investigation
is needed to better understand this group of patients and to improve
their survival.
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SIROLIMUS, TACROLIMUS AND FLUCONAZOLE PHARMACOKINETICS IN
PEDIATRIC BMT RECIPIENTS
Goyal, R.K.1, Venkataramanan, R.2, Mada, S.R.2, Krasowski, M.3,
Grupp, S.4, Wall, D.5, Bunin, N.4, Pulsipher, M.6. 1Children’s Hospital
of Pittsburgh, Pittsburgh, PA; 2University of Pittsburgh School of Phar-
macy, Pittsburgh, PA; 3UPMC Pathology, Pittsburgh, PA; 4Children’s
Hospital of Philadelphia, Philadelphia, PA; 5Texas Transplant Institute,
San Antonio, TX; 6University of Utah School of Medicine, Salt Lake
City, UT.
Sirolimus (SRL) and tacrolimus (TAC) combination is a promis-
ing GVHD prophylaxis strategy with demonstrated efficacy in
adults undergoing BMT. Sirolimus potentates the effects of calci-
neurin inhibitors on thrombotic microangiopathy. Fluconazole
and other azoles are expected to result in increased plasma concen-
trations of SRL and TAC. There is little data on pharmacokinetic
interactions between SRL and TAC in BMT recipients.
SRL and TAC pharmacokinetic profiles were evaluated in 40 pe-
diatric BMT recipients with high-risk ALL treated on a pilot trial
using SRL-based GVHD prophylaxis. Mean age at transplant was
10 y (4–22 y). Preparative regimen: TBI 1200 cGy, thiotepa 10
mg/kg, and cyclophosphamide 120 mg/kg. GVHD prophylaxis:
continuous infusion TAC (0.3 mg/kg; target 5–10 ng/mL), IV
methotrexate (5 mg/m2, 4–5 doses) and oral SRL (2.5 mg/m2/d, 4
mg/d max, target 3–12 ng/mL). 26 patients also received flucona-
zole prophylaxis (100–400 mg once daily).
Whole blood SRL and TAC concentrations were measured by
liquid chromatography with tandem-mass spectrometry, while
blood fluconazole levels were measured by HPLC.
SRL conc. normalized to dose (mean6SD, ng/mL/mg) were:
trough level before the dose (C0) 3.37 6 2.09, maximum (Cmax)
8.33 6 6.09, and 24 hours later (C24) 3.89 6 2.37. C0 and C24
were similar and correlated well, indicating achievement of steady
state. Time to max. conc. (Tmax) mean 6 (SD) ng/ml was 4.89 6
(4.63) hrs; Cmin 3.90 6 (2.37); Cmax mean 6 SD of 8.33 6 (6.09).
TAC Css ranged from 2.29 to 21.56 with a mean 6 SD of 7.79 6
(5.25) mg/ml. Fluconazole Cmin ranged from 0.03 to 4.36 mg/ml
(1.71 6 1.32 mg/ml) and Cmax ranged from 0.07 to 15.66 mg/ml
(5.41 6 4.52 mg/ml) after oral dose. The Cmin ranged from 1.47
to 4.71 mg/ml (2.97 6 1.19 mg/ml) and Cmax ranged from 2.46 to
12.80mg/ml (6.256 3.14mg/ml) after IV dose. The correlation be-
tween sirolimus and fluconazole trough concentrations was poor
(R25 0.1135). The correlation between tacrolimus and fluconazole
trough concentrations was also poor (R2 5 0.043).
Our findings show a large variability in the exposure of sirolimus,
tacrolimus, and fluconazole and support the need for SRL andTAC
therapeutic monitoring and dose adjustments based on steady state
blood levels. While fluconazole is known to decrease clearance of
TAC and SRL, lack of correlation between trough fluconazole,
SRL andTAC concentrations suggests factors other thanmetabolic
inhibition contribute to the observed inter-patient variability.
